Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study ; volume:103 ; number:6 ; day:13 ; month:3 ; year:2024 ; pages:1931-1940 ; date:6.2024
Annals of hematology ; 103, Heft 6 (13.3.2024), 1931-1940, 6.2024

Creator: Palandri, F.
Auteri, G.
Abruzzese, E.
Caocci, G.
Bonifacio, M.
Mendicino, F.
Latagliata, R.
Iurlo, A.
Branzanti, F.
Garibaldi, B.
Trawinska, M. M.
Cattaneo, D.
Krampera, M.
Mulas, O.
Martino, E. A.
Cavo, M.
Vianelli, N.
Impera, S.
Efficace, F.
Heidel, F.
Breccia, M.
Elli, E. M.
Palumbo, G. A.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00277-024-05704-0

URN: urn:nbn:de:101:1-2407222101124.836202779833

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Palandri, F.
Auteri, G.
Abruzzese, E.
Caocci, G.
Bonifacio, M.
Mendicino, F.
Latagliata, R.
Iurlo, A.
Branzanti, F.
Garibaldi, B.
Trawinska, M. M.
Cattaneo, D.
Krampera, M.
Mulas, O.
Martino, E. A.
Cavo, M.
Vianelli, N.
Impera, S.
Efficace, F.
Heidel, F.
Breccia, M.
Elli, E. M.
Palumbo, G. A.
SpringerLink (Online service)

Other Objects (12)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Management of myelofibrosis after ruxolitinib failure

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Management of myelofibrosis after ruxolitinib failure

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Management of myelofibrosis after ruxolitinib failure

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Management of myelofibrosis after ruxolitinib failure

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Management of myelofibrosis after ruxolitinib failure

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Management of myelofibrosis after ruxolitinib failure

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene

Related objects

Reset password